Esfahani Mahsa, Sahafi Sahar, Derakhshandeh Ali, Moghaddas Azadeh
Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Oncology and Hematology, Isfahan University of Medical Sciences, Isfahan, Iran.
Asia Pac J Clin Nutr. 2018;27(3):503-511. doi: 10.6133/apjcn.042017.10.
Cachexia is a paraneoplastic syndrome that affects the large majority of patients with end-stage cancer. No known therapy exists to effectively overcome the severe symptoms of cachexia, which include anorexia, weight loss and fatigue. This study considered the results of both experimental and clinical studies to evaluate the suitability of L-carnitine and its derivatives as potential therapies for cachexia in patients with cancer.
All available English-language papers on the use of L-carnitine in patients with cachexia related to cancer, including reviews, case reports, case series, and clinical trials, were obtained by searching multiple databases, including all Elsevier publications, Web of Knowledge, PubMed, Scopus, clinical trials, and the Cochrane database of systematic reviews.
The protective effects of L-carnitine were extracted from the literature review based on critical mechanisms involved in skeletal muscle loss, including increased proteolysis, impaired protein synthesis, myonuclear apoptosis, oxidative stress, and mitochondrial dysfunction. The results of this process favored L-carnitine supplementation in patients with cancer-related cachexia. Nitrogen balance was improved either through the increase of protein synthesis or by reduction in proteolysis, inhibiting apoptosis or reversing inflammatory processes.
Although clinical studies are inconclusive, studies in animal models support L-carnitine administration to prevent oxidative stress and ameliorate mitochondrial function. L-carnitine supplementation leads to beneficial effects on several critical mechanisms involved in pathologic skeletal muscle loss and improved fatigue-related parameters in patients with cancer. However, more well-designed, double-blinded, randomized clinical trials are necessary to establish L-carnitine supplementation as a therapeutic strategy for cachexia.
恶病质是一种副肿瘤综合征,影响绝大多数终末期癌症患者。目前尚无已知疗法能有效克服恶病质的严重症状,这些症状包括厌食、体重减轻和疲劳。本研究综合了实验研究和临床研究的结果,以评估左旋肉碱及其衍生物作为癌症患者恶病质潜在治疗方法的适用性。
通过检索多个数据库,包括所有爱思唯尔出版物、知识网络、PubMed、Scopus、临床试验以及Cochrane系统评价数据库,获取了所有关于左旋肉碱用于与癌症相关恶病质患者的英文文献,包括综述、病例报告、病例系列和临床试验。
基于骨骼肌损失所涉及的关键机制,包括蛋白水解增加、蛋白质合成受损、肌核凋亡、氧化应激和线粒体功能障碍,从文献综述中提取了左旋肉碱的保护作用。这一过程的结果支持对癌症相关恶病质患者补充左旋肉碱。通过增加蛋白质合成或减少蛋白水解、抑制凋亡或逆转炎症过程,改善了氮平衡。
尽管临床研究尚无定论,但动物模型研究支持给予左旋肉碱以预防氧化应激和改善线粒体功能。补充左旋肉碱对病理骨骼肌损失所涉及的几个关键机制产生有益影响,并改善癌症患者与疲劳相关的参数。然而,需要更多设计良好的双盲随机临床试验,以确立补充左旋肉碱作为恶病质的治疗策略。